International Conference on Population and Development

BELLUS Health to Present Late-Breaking Clinical Data from the Phase 2b SOOTHE Trial of BLU-5937 at the ATS 2022 International Conference

Retrieved on: 
Monday, May 2, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, RCC, Nasdaq, Health, American Thoracic Society, Company, ATS, Patient, Quality of life, Therapy, International Conference on Population and Development, 2021 Essex County Council election, Chronic cough, Conference, TSX, Quality, BLU, Pharmaceutical industry

Following the conference, the presentation materials will be available in the Scientific Publications section of BELLUS Health's website at www.bellushealth.com .

Key Points: 
  • Following the conference, the presentation materials will be available in the Scientific Publications section of BELLUS Health's website at www.bellushealth.com .
  • BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications.
  • The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC.
  • BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.

One Drop Presents Clinical Health Outcomes Demonstrating the Impact of Long-term Use of its Award-Winning Digital Platform

Retrieved on: 
Thursday, April 28, 2022
Walmart, Deloitte Technology Fast 500, Blood, Publication, International Conference on Population and Development, Honda advanced technology, Algorithm, Android, Apple Store, FDA, One drop, IOS, ATTD, Food, CVS, Conference, Biomarker, Treatment, Machine learning, Multimedia, Best Buy, Research, View, CGM, Industry, Blood pressure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Health, Pharmaceutical industry, Medical device, Diabetes, Amazon

NEW YORK , April 28, 2022 /PRNewswire/ -- One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented clinical health outcomes associated with long-term use with its award-winning digital platform at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2022). New peer-reviewed research demonstrates that people with diabetes using One Drop sustained clinically and statistically significant reductions in average blood glucose beyond six months and one year, citing meaningful reductions in estimated A1C (eA1C).

Key Points: 
  • Members using One Drop for at least six months reduced their average blood glucose by 26.5 mg/dL, translating to a 0.9% reduction in estimated A1C.
  • More than 60 peer-reviewed clinical studies, publications, and presentations demonstrate the results and clinical strengths of One Drop's existing digital health platform , including improved health outcomes and estimated cost savings of $2,450 per person per year.
  • To date, One Drop has gathered over 38 billion longitudinal health data points from approximately 1.5 million members worldwide.
  • Notable industry accolades for One Drop include ranking on the NYC Digital Health 100 and Deloitte Technology Fast 500 .

Youth Leaders Win Prestigious Award to Attend, Provide Programming Insight for International Conference on Family Planning

Retrieved on: 
Wednesday, March 16, 2022
Adolescence, Department, Johns Hopkins Bloomberg School of Public Health, Universal health care, World, Johns Hopkins University, Reproductive health, Conference, Organization, Grey Literature International Steering Committee, United Nations Population Fund, Social change, ICFP, Institute, Science, Bill, World Health Organization, Family, Public health, SRHR, Leadership, Research, International Conference on Population and Development, Birth control, Mobile phone, Population

BALTIMORE, March 16, 2022 /PRNewswire/ -- Fifty youth leaders working in family planning and sexual and reproductive health and rights (SRHR) have been awarded scholarships to attend the International Conference on Family Planning (ICFP) this year in Pattaya City, Thailand, 14-17 November. The awardees will also help shape the content of the conference sessions.

Key Points: 
  • BALTIMORE, March 16, 2022 /PRNewswire/ -- Fifty youth leaders working in family planning and sexual and reproductive health and rights (SRHR) have been awarded scholarships to attend the International Conference on Family Planning (ICFP) this year in Pattaya City, Thailand, 14-17 November.
  • More than 300 youth worldwide applied for the honor, which is named the Youth Trailblazer Award in recognition of the important leadership and innovation youth bring to family planning and SRHR.
  • The Youth Trailblazer Award selection process was led and managed by two winners of the 120 Under 40 Family Planning Champions , and included additional youth as reviewers.
  • Since 2009, the International Conference on Family Planning has served as a strategic inflection point for the global reproductive health community.

Youth Leaders Win Prestigious Award to Attend, Provide Programming Insight for International Conference on Family Planning

Retrieved on: 
Wednesday, March 16, 2022
Adolescence, Department, Johns Hopkins Bloomberg School of Public Health, Universal health care, World, Johns Hopkins University, Reproductive health, Conference, Organization, Grey Literature International Steering Committee, United Nations Population Fund, Social change, ICFP, Institute, Science, Bill, World Health Organization, Family, Public health, SRHR, Leadership, Research, International Conference on Population and Development, Birth control, Mobile phone, Population

BALTIMORE, March 16, 2022 /PRNewswire/ -- Fifty youth leaders working in family planning and sexual and reproductive health and rights (SRHR) have been awarded scholarships to attend the International Conference on Family Planning (ICFP) this year in Pattaya City, Thailand, 14-17 November. The awardees will also help shape the content of the conference sessions.

Key Points: 
  • BALTIMORE, March 16, 2022 /PRNewswire/ -- Fifty youth leaders working in family planning and sexual and reproductive health and rights (SRHR) have been awarded scholarships to attend the International Conference on Family Planning (ICFP) this year in Pattaya City, Thailand, 14-17 November.
  • More than 300 youth worldwide applied for the honor, which is named the Youth Trailblazer Award in recognition of the important leadership and innovation youth bring to family planning and SRHR.
  • The Youth Trailblazer Award selection process was led and managed by two winners of the 120 Under 40 Family Planning Champions , and included additional youth as reviewers.
  • Since 2009, the International Conference on Family Planning has served as a strategic inflection point for the global reproductive health community.

Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting

Retrieved on: 
Friday, March 11, 2022
Safety, Clinical trial, Senior, PMDA, Medication, Research, Autumn, FDA, International Conference on Population and Development, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Alzheimer's disease, Conference, Amyloid beta, Biologics license application, ARIA, Amyloid, Medicines and Healthcare products Regulatory Agency, African Americans, Pharmaceuticals and Medical Devices Agency, Neurodegeneration, Disease, Food, AD, Pharmaceutical industry, Clarity, Eisai

The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations.

Key Points: 
  • The lecanemab data and additional research findings from Eisai's clinical development programs will be featured in 13 presentations.
  • Lecanemab was granted Breakthrough Therapy and Fast Track designations by the U.S. Food and Drug Administration (FDA) in June and December 2021, respectively.
  • Additionally, the readout of the Phase 3 confirmatory Clarity AD clinical trial will occur in the Fall of 2022.
  • There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.

Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results

Retrieved on: 
Friday, November 5, 2021
Safety, Progression-free survival, Anal cancer, Letrozole, AIO, Colorectal cancer, American, PD, CEACAM6, Oncolytics Biotech, AB, Pelareorep, Radiation, NASDAQ, International Conference on Population and Development, Roche, Technology, LINK, Investor relations, Inflammation, Gastrointestinal cancer, International, IRENE, Association, TSX, Neoplasm, Company, Conference, KRAS, Breast cancer, Spear, PR, CD8, Triple-negative breast cancer, Survival, Pancreatic cancer, Poster, Patient, ONC, Pharmaceutical industry, Medical imaging, Oil, Vaccine, Lithium

SAN DIEGO and CALGARY, AB, Nov. 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended September 30, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended September 30, 2021.
  • Operating expense for the third quarter of 2021 was $2.9 million, compared to $2.5 million in the third quarter of 2020.
  • R&D expense for the third quarter of 2021 was $3.3 million, compared to $3.9 million in the third quarter of 2020.
  • Net cash used in operating activities for the third quarter of 2021 was $3.7 million, compared to $6.1 million for the third quarter of 2020.

Oncolytics Biotech® Reports 2021 Third Quarter Development Highlights and Financial Results

Retrieved on: 
Friday, November 5, 2021
Safety, Progression-free survival, Anal cancer, Letrozole, AIO, Colorectal cancer, American, PD, CEACAM6, Oncolytics Biotech, AB, Pelareorep, Radiation, NASDAQ, International Conference on Population and Development, Roche, Technology, LINK, Investor relations, Inflammation, Gastrointestinal cancer, International, IRENE, Association, TSX, Neoplasm, Company, Conference, KRAS, Breast cancer, Spear, PR, CD8, Triple-negative breast cancer, Survival, Pancreatic cancer, Poster, Patient, ONC, Pharmaceutical industry, Medical imaging, Oil, Vaccine, Lithium

SAN DIEGO and CALGARY, AB, Nov. 5, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended September 30, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and development highlights for the quarter ended September 30, 2021.
  • Operating expense for the third quarter of 2021 was $2.9 million, compared to $2.5 million in the third quarter of 2020.
  • R&D expense for the third quarter of 2021 was $3.3 million, compared to $3.9 million in the third quarter of 2020.
  • Net cash used in operating activities for the third quarter of 2021 was $3.7 million, compared to $6.1 million for the third quarter of 2020.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Retrieved on: 
Monday, September 20, 2021
Therapy, Bossard Holding AG, Pembrolizumab, Carboplatin, Hoffmann-La Roche, OTC, City of Hope, Conference, Ageing, Boucekastichus, Squamous cell carcinoma, ONC, Wilms' tumor, Light, City, Breast cancer, Pfizer UK, Optimism, Roche, Disease, Technology, Pfizer, Etoposide, Maintenance, Radiation, Survival, Lead, COTA, BMS, NYSE, Data visualization, Oncology, Neoplasm, Partnership, CURE, Oncolytics Biotech, Patient, NASDAQ, FDA, Cancer, MRK, Bristol Myers Squibb, Kidney cancer, Pelareorep, Trastuzumab, Large-cell lung carcinoma, Risk, BMY, HCP, Trastuzumab emtansine, TSX, News, Immunotherapy, NHS, CO, International Conference on Population and Development, PFE, Pharmaceutical industry, Medical imaging

VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster. However, in many ways, 2021 has witnessed several major developments that continue to provide optimism within the oncology field, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC),Roche Holding AG (OTC: RHHBY), Merck &. Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Pfizer Inc. (NYSE: PFE).

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Retrieved on: 
Monday, September 20, 2021
Therapy, Bossard Holding AG, Pembrolizumab, Carboplatin, Hoffmann-La Roche, OTC, City of Hope, Conference, Ageing, Boucekastichus, Squamous cell carcinoma, ONC, Wilms' tumor, Light, City, Breast cancer, Pfizer UK, Optimism, Roche, Disease, Technology, Pfizer, Etoposide, Maintenance, Radiation, Survival, Lead, COTA, BMS, NYSE, Data visualization, Oncology, Neoplasm, Partnership, CURE, Oncolytics Biotech, Patient, NASDAQ, FDA, Cancer, MRK, Bristol Myers Squibb, Kidney cancer, Pelareorep, Trastuzumab, Large-cell lung carcinoma, Risk, BMY, HCP, Trastuzumab emtansine, TSX, News, Immunotherapy, NHS, CO, International Conference on Population and Development, PFE, Pharmaceutical industry, Medical imaging

In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.